Escitalopram updated on 07-01-2025

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S18237
R76495		 Laspro, 2024 Oral clefts (ICD 10 codes Q35 or Q36 or Q37) during pregnancy (anytime or not specified) excluded nested case control unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 1.14 [1.02;1.29]
excluded (exposition period) 		278/-   11,820/- 12,098 -
ref
S7472
R22350		 Anderson, 2020 Any oral cleft 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.76 [0.39;1.51] -/-   0/- - -
ref
S8218
R25689		 Jordan, 2016 Oro‐facial clefts 3 months or more before pregnancy or1st trimester excluded retrospective cohort (registry) unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 1.61 [0.83;3.10]
excluded (exposition period) 		9/3,236   861/506,155 870 3,236
ref
S5890
R14788		 Ban (Controls unexposed, disease free), 2014 Orofacialcleft 1st trimester retrospective cohort (claims database) unexposed, disease free Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.40 [0.02;6.37] C 0/933   438/325,294 438 933
ref
Total 2 studies 0.73 [0.38;1.41] 438 933
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 0.76[0.39; 1.51]--94%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Ban (Controls unexposed, disease free), 2014Ban, 2014 1 0.40[0.02; 6.37]4389336%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (2 studies) I2 = 0% 0.73[0.38; 1.41]4389330.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, disease free;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.40[0.02; 6.37]438933 -NABan (Controls unexposed, disease free), 2014 1 case control studiescase control studies 0.76[0.39; 1.50]-- -NAAnderson, 2020 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.73[0.38; 1.41]4389330%NAAnderson, 2020 Ban (Controls unexposed, disease free), 2014 2 Tags Adjustment   - No  - No 0.40[0.02; 6.37]438933 -NABan (Controls unexposed, disease free), 2014 1   - Yes  - Yes 0.76[0.39; 1.50]-- -NAAnderson, 2020 1 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.76[0.39; 1.50]-- -NAAnderson, 2020 1   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.40[0.02; 6.37]438933 -NABan (Controls unexposed, disease free), 2014 1 All studiesAll studies 0.73[0.38; 1.41]4389330%NAAnderson, 2020 Ban (Controls unexposed, disease free), 2014 20.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 0.73[0.38; 1.41]4389330%NAAnderson, 2020 Ban (Controls unexposed, disease free), 2014 20.510.01.0